Identification | Back Directory | [Name]
SDZ 281 977 | [CAS]
150779-71-8 | [Synonyms]
SDZ 281 977 SDZ-LAP 977 Benzoic acid, 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxy-, methyl ester | [Molecular Formula]
C18H20O5 | [MDL Number]
MFCD00920170 | [MOL File]
150779-71-8.mol | [Molecular Weight]
316.35 |
Hazard Information | Back Directory | [Uses]
SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A. | [in vivo]
Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment[1]. | [References]
[1] Cammisuli S, et al. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int J Cancer. 1996 Jan 26;65(3):351-9. DOI:10.1002/(SICI)1097-0215(19960126)65:33.0.CO;2-D |
|
Company Name: |
MedChemExpress
|
Tel: |
021-58955995 |
Website: |
www.medchemexpress.com |
|